Bringing hope through science
FDA approval of PEPAXTO - Webcast
In conjunction with the FDA approval of PEPAXTO, Oncopeptides hosted a webcast Monday March 1, 2021, including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker, and CFO Anders Martin-Löf. The webcast was recorded.
Vision of Oncopeptides
“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
CEO Marty J Duvall interviewed by Di.TV
In conjunction with the FDA approval, Oncopeptides' CEO Marty J Duvall was interviewed by the Swedish economy TV channel Di.TV Börsmorgon. See the interview (after about 30 sek the interview turns into English).
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
Read more
Webcast - Cowen 41st Annual Health Care Conference
Oncopeptides presents at Cowen 41st Annual Health Care Conference March 3, 2021, at 17:00 (CET).
Released
Year-end report 2020
”A year of transformation”
CEO Marty J Duvall
For further information, please contact:
Linda Holmström
Director of Investor Relations
linda.holmstrom@oncopeptides.com
+46 70 873 40 95
Press release -
FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
Read press release
Seminar at the Embassy of Sweden Washington DC
The Embassy of Sweden in Washington DC, Oncopeptides AB, Dana Farber and Uppsala University hosted a virtual seminar on February 2nd,“A Swedish American Journey of Cancer Research”.
Cultures & Values
We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.